Skip to main content

Antibiotic-Associated Diarrhea

1
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
BIO-K+ CL-1285®Phase 31 trial
Active Trials
NCT00958308Completed255Est. Apr 2009
Adamed
AdamedPoland - Czosnów
2 programs
Lactobacillus rhamnosus ATCC 53103 & Lactobacillus reuteri DSM 29063N/A1 trial
Lactobacillus rhamnosus ATCC 53103 and Lactobacillus reuteri DSM 29063N/A
Active Trials
NCT04277156Unknown892Est. Dec 2023
Innovation Pharmaceuticals
1 program
1 - Fermented dairy drinkN/A1 trial
Active Trials
NCT02900196Terminated136Est. Aug 2017
Plus Therapeutics
1 program
BIO-K+ CL-1285®PHASE_3
Sandoz
SandozAustria - Kundl
1 program
LRG-002PHASE_31 trial
Active Trials
NCT04321460Completed520Est. Jan 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozLRG-002
BiocorpBIO-K+ CL-1285®
AdamedLactobacillus rhamnosus ATCC 53103 & Lactobacillus reuteri DSM 29063
Innovation Pharmaceuticals1 - Fermented dairy drink

Clinical Trials (4)

Total enrollment: 1,803 patients across 4 trials

NCT04321460SandozLRG-002

Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.

Start: Oct 2020Est. completion: Jan 2021520 patients
Phase 3Completed
NCT00958308BiocorpBIO-K+ CL-1285®

Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection

Start: Dec 2008Est. completion: Apr 2009255 patients
Phase 3Completed
NCT04277156AdamedLactobacillus rhamnosus ATCC 53103 & Lactobacillus reuteri DSM 29063

L Rhamnosus ATCC 53103 & L Reuteri DSM 29063 Compared With L Rhamnosus ATCC 53103 for Preventing AAD in Children

Start: Feb 2020Est. completion: Dec 2023892 patients
N/AUnknown
NCT02900196Innovation Pharmaceuticals1 - Fermented dairy drink

Effect of a Fresh Fermented Dairy Drink Product Consumption on Antibiotic Associated Diarrhea and Gastro-Intestinal Disorders

Start: Sep 2016Est. completion: Aug 2017136 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.